Premium
Double‐blind, placebo‐controlled study of the efficacy of nandrolone laurate in the treatment of dobermanns with subclinical hepatitis
Author(s) -
Mandigers P. J. J.,
Horspool L. J. L.,
Ingh T. S. G. A. M.,
Teske E.,
Bode P.,
Rothuizen J.
Publication year - 2005
Publication title -
veterinary record
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 99
eISSN - 2042-7670
pISSN - 0042-4900
DOI - 10.1136/vr.157.11.313
Subject(s) - subclinical infection , nandrolone , medicine , double blind , placebo , gastroenterology , clinical trial , hepatitis , significant difference , hepatitis a virus , pathology , immunology , virus , alternative medicine , anabolism
Twenty‐one three‐year‐old dobermanns with subclinical hepatitis were treated with nandrolone laurate or a placebo in a double‐blind trial. The dogs were scored clinically before and after four months of treatment and they were evaluated by clinical biochemistry and liver biopsies. After the treatment no significant differences were observed between the two groups in any of the clinical biochemistry values; eight of the 21 dogs had no histological evidence of hepatitis and five other dogs had improved, but there was no significant difference between the responses of the two groups.